Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apoptosis.
The DOI matches its Crossref record; 38 of the 39 references it cites were found in a registry or an index.
Abstract
Bisphosphonate inhibition of bone resorption was proposed to be due to osteoclast apoptosis. We tested this hypothesis for both the N-containing bisphosphonates alendronate and risedronate, which inhibit farnesyldiphosphate synthase and thus protein isoprenylation, and for clodronate and etidronate, which are metabolized to adenosine triphosphate (ATP) analogs. We found, in dose-response studies, that alendronate and risedronate inhibit bone resorption (in pit assays) at doses tenfold lower than those reducing osteoclast number. At an N-bisphosphonate dose that inhibited resorption and induced apoptosis, the antiapoptotic caspase inhibitor, Z-VAD-FMK, maintained osteoclast (Oc) number but did not prevent inhibition of resorption. Furthermore, when cells were treated with either alendronate alone or in combination with Z-VAD-FMK for 24 or 48 h, subsequent addition of geranylgeraniol, which restores geranylgeranylation, returned bone resorption to control levels. On the other hand, Z-VAD-FMK did block etidronate and clodronate inhibition of resorption. Moreover, in cells treated with etidronate, but not alendronate or risedronate, Z-VAD-FMK also prevented actin disruption, an early sign of osteoclast inhibition by bisphosphonates. These observations indicate that, whereas induction of apoptosis plays a major role in etidronate and clodronate inhibition of resorption, alendronate and risedronate suppression of bone resorption is independent of their effects on apoptosis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although bisphosphonates are clearly capable of inducing osteoclast apoptosis, this apoptotic response does not appear to be an essential component of their ability to suppress bone resorption (142).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [142]
Citations
Cites
Ridley, A. J., & Hall, A. (1992) · Cell · doi:10.1016/0092-8674(92)90163-7 · Cited by 4,468
Nobes, C. D., & Hall, A. (1995) · Cell · doi:10.1016/0092-8674(95)90370-4 · Cited by 4,412
The small GTP-binding protein rac regulates growth factor-induced membrane ruffling
Ridley, A. J., Paterson, H. F., Johnston, C. L., Diekmann, D., & Hall, A. (1992) · Cell · doi:10.1016/0092-8674(92)90164-8 · Cited by 3,652
Luckman, S. P., Hughes, D. E., Coxon, F. P., Russell, R. G. G., & Dr. Rogers, M. J. (1998) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1998.13.4.581 · Cited by 1,176
Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo
Hughes, D. E., Wright, K. R., Uy, H. L., Sasaki, A., Yoneda, T., Roodman, D. G., Mundy, G. R., & Dr. Boyce, B. F. (1995) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650101008 · Cited by 1,040
Sato, M., Grasser, W., Endo, N., Akins, R., Simmons, H., Thompson, D. D., Golub, E., & Rodan, G. A. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115539 · Cited by 1,004
Self-citationDunford, J. E., Thompson, K., Coxon, F. P., Luckman, S. P., Hahn, F. M., Poulter, C. D., Ebetino, F. H., & Rogers, M. J. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38786-5 · Cited by 900
Fisher, J. E., Rogers, M. J., Halasy, J. M., Luckman, S. P., Hughes, D. E., Masarachia, P. J., Wesolowski, G., Russell, R. G. G., Rodan, G. A., & Reszka, A. A. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.1.133 · Cited by 676
Self-citationFarnesyl Pyrophosphate Synthase Is the Molecular Target of Nitrogen-Containing Bisphosphonates
van Beek, E., Pieterman, E., Cohen, L., Löwik, C., & Papapoulos, S. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.1499 · Cited by 496
Frith, J. C., Mönkkönen, J., Blackburn, G. M., Russell, R. G. G., & Rogers, M. J. (1997) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1997.12.9.1358 · Cited by 437
Research works printed but not linked: 1
- Benford, 1999, Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates, Mol Pharmacol, 56, 131, 10.1124/mol.56.1.131 · doi:10.1124/mol.56.1.131 · Paper page
Cited by
Rauch, F., & Glorieux, F. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16051-0 · Cited by 1,167
Kearns, A. E., Khosla, S., & Kostenuik, P. J. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0014 · Cited by 824
Beyond the gap: functions of unpaired connexon channels
Goodenough, D. A., & Paul, D. L. (2003) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1072 · Cited by 729
Molecular Mechanisms of Action of Bisphosphonates: Current Status
Roelofs, A. J., Thompson, K., Gordon, S., & Rogers, M. J. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0843 · Cited by 568
Biochemical and molecular mechanisms of action of bisphosphonates
Rogers, M. J., Crockett, J. C., Coxon, F. P., & Mönkkönen, J. (2011) · Bone · doi:10.1016/j.bone.2010.11.008 · Cited by 530
Metadata
- Authors
- Halasy-Nagy, J. M., Rodan, G. A., & Reszka, A. A.
- Corresponding author
- Reszka, A.A.
- Venue
- Bone
- Publisher
- Elsevier BV
- Published
- 2001-12
- Volume
- 29
- Issue
- 6
- Pages
- 553-559
- ISSN
- 1873-2763 (ISSN-L)
- 8756-3282
- OpenAlex
- W2024098071
- Cited by
- 190
- References
- 39
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 2 · 2023: 3 · 2022: 3 · 2021: 5 · 2020: 4 · 2019: 5 · 2018: 4 · 2017: 4 · 2016: 9 · 2015: 5 · 2014: 9 · 2013: 8 · 2012: 11
- FWCI
- 4.77
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- Bone (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Keywords
- bisphosphonates, alendronate, risedronate, etidronate, clodronate, bone resorption, osteoclast apoptosis, osteoclast number, farnesyl diphosphate synthase, isoprenylation, geranylgeranylation, geranylgeraniol, caspase inhibition, z-VAD-fmk, ATP analogs
- MeSH terms
- Risedronic Acid, Actins, Animals, Bone Resorption, Cytoskeleton, Osteoclasts, Etidronic Acid, Apoptosis, Alendronate, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apoptosis. https://app.cochat.ai/papers/10.1016/s8756-3282(01)00615-9
- The paper
- Halasy-Nagy, J. M., Rodan, G. A., & Reszka, A. A. (2001). Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apoptosis. Bone. https://doi.org/10.1016/s8756-3282(01)00615-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.